AR125122A1 - Actividad antiviral de inhibidores de vps34 - Google Patents
Actividad antiviral de inhibidores de vps34Info
- Publication number
- AR125122A1 AR125122A1 ARP210103260A ARP210103260A AR125122A1 AR 125122 A1 AR125122 A1 AR 125122A1 AR P210103260 A ARP210103260 A AR P210103260A AR P210103260 A ARP210103260 A AR P210103260A AR 125122 A1 AR125122 A1 AR 125122A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- c3alkyl
- c6alkyl
- phenyl
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos de tratamiento de infecciones virales, tales como infecciones por coronavirus, en pacientes que lo necesitan, que comprenden administrar a dichos pacientes un inhibidor de VPS34. Reivindicación 1: Un método para paliar o tratar una infección viral en un paciente que lo necesite, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, donde: R¹ se selecciona entre C₁-C₃alquilo y ciclopropilo; R² se selecciona entre el grupo que consiste en H, C₁-C₃haloalquilo, y C₁-C₃alquilo; A se selecciona entre: los compuestos del grupo de fórmulas (2); cada R³ se selecciona en forma independiente entre el grupo que consiste en R⁶, C₁-C₆alquilo, amino, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino, y C₁-C₃alcoxiC₁-C₃alquilo, donde cada uno de C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una instancia de R⁶, y cada C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una o más instancias independientes de halógeno; R⁴ se selecciona entre el grupo que consiste en C₁-C₆alquilo, C₁-C₆alcoxi, C₁-C₆haloalquilo, C₃-C₆cicloalquilo, y fenilo, donde fenilo está opcionalmente sustituido con una o más instancias de un sustituyente seleccionado en forma independiente entre el grupo que consiste en fluoro, cloro, metilo, metoxi, dimetilamino, trifluorometoxi, trifluorometilo, y ciclopropilo; R⁵ se selecciona entre el grupo que consiste en halógeno, C₁-C₆alquilo, C₁-C₆alcoxi, C₁-C₆haloalquilo, y C₃-C₆cicloalquilo; cada R⁶ se selecciona en forma independiente entre el grupo que consiste en fenilo, heteroarilo monocíclico, C₃-C₆cicloalquilo, y heterociclilo, donde cada fenilo, heteroarilo monocíclico, C₃-C₆cicloalquilo, y heterociclilo está opcionalmente sustituido con una o más instancias de R⁷; y cada R⁷ se selecciona en forma independiente entre el grupo que consiste en halógeno, amino, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino y C₁-C₃alcoxiC₁-C₃alquilo, C₁-C₃alcoxi, C₁-C₃haloalcoxi, C₃-C₆cicloalquilo, C₁-C₃haloalquilo, y C₁-C₃alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118509P | 2020-11-25 | 2020-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125122A1 true AR125122A1 (es) | 2023-06-14 |
Family
ID=78957685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103260A AR125122A1 (es) | 2020-11-25 | 2021-11-25 | Actividad antiviral de inhibidores de vps34 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220184093A1 (es) |
| EP (1) | EP4251165A1 (es) |
| JP (1) | JP2023550641A (es) |
| CN (1) | CN117241829A (es) |
| AR (1) | AR125122A1 (es) |
| CA (1) | CA3199995A1 (es) |
| TW (1) | TW202237130A (es) |
| WO (1) | WO2022115558A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070259844A1 (en) * | 2003-06-20 | 2007-11-08 | Vgx Pharmaceuticals | Antiviral Compositions And Methods Of Using The Same |
| WO2009014633A1 (en) * | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
| WO2014043442A1 (en) * | 2012-09-14 | 2014-03-20 | Children's Medical Center Corporation | Inhibition of viral infection-triggered asthma with c-kit inhibitor |
| US10675296B2 (en) * | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| LT3672962T (lt) | 2017-08-23 | 2022-05-10 | Sprint Bioscience Ab | Morfolinilpiridono junginiai |
| WO2021045836A1 (en) * | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
-
2021
- 2021-11-24 US US17/534,771 patent/US20220184093A1/en not_active Abandoned
- 2021-11-24 CA CA3199995A patent/CA3199995A1/en active Pending
- 2021-11-24 CN CN202180090242.2A patent/CN117241829A/zh active Pending
- 2021-11-24 EP EP21827785.3A patent/EP4251165A1/en active Pending
- 2021-11-24 JP JP2023531514A patent/JP2023550641A/ja active Pending
- 2021-11-24 WO PCT/US2021/060758 patent/WO2022115558A1/en active Application Filing
- 2021-11-25 TW TW110143939A patent/TW202237130A/zh unknown
- 2021-11-25 AR ARP210103260A patent/AR125122A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202237130A (zh) | 2022-10-01 |
| CA3199995A1 (en) | 2022-06-02 |
| JP2023550641A (ja) | 2023-12-04 |
| US20220184093A1 (en) | 2022-06-16 |
| WO2022115558A1 (en) | 2022-06-02 |
| EP4251165A1 (en) | 2023-10-04 |
| CN117241829A (zh) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| DOP2022000183A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| PE20220762A1 (es) | Derivados de acido itaconico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| AR081261A1 (es) | Metodos para tratar afecciones virales | |
| DOP2021000077A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| UY38096A (es) | Inhibidores de arginasa y sus métodos de uso | |
| EA202190854A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| AR125122A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| DOP2023000256A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| AR118043A1 (es) | DERIVADOS DE INDAZOLIL-ISOXAZOL COMO INHIBIDORES DE c-KIT QUINASA | |
| AR125118A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática |